Malignant Neoplasm of the Lung B004

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/m/malignant-neoplasm-lung-b004-c33c34

Last amended

Factors in CCPS as at 18 July 2007 (B004)

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/sop-information/sops-and-supporting-information-alphabetic-listing/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004

Last amended

A course of therapeutic radiation to the thorax

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/course-therapeutic-radiation-thorax

Last amended

Alcohol consumption

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/alcohol-consumption

Last amended

Asbestosis

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/asbestosis

Last amended

Atomic radiation

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/atomic-radiation

Last amended

Being in an atmosphere with a visible tobacco smoke haze

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/being-atmosphere-visible-tobacco-smoke-haze

Last amended

Being on land in Vietnam or at sea in Vietnamese waters or consuming water from estuarine Vietnamese waters

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/being-land-vietnam-or-sea-vietnamese-waters-or-consuming-water-estuarine-vietnamese-waters

Last amended

Berylliosis

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/berylliosis

Last amended

Chronic respiratory disease

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/chronic-respiratory-disease

Last amended

Cigar smoking

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/cigar-smoking

Last amended

Cigarette smoking

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/cigarette-smoking

Last amended

Exposure to an industrial coke oven

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/exposure-industrial-coke-oven

Last amended

Exposure to radon

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/exposure-radon

Last amended

Exposure to TCDD

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/exposure-tcdd

Last amended

Heavy exposure to diesel engine exhaust

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/heavy-exposure-diesel-engine-exhaust

Last amended

Inhaling fumes of a specified substance

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/inhaling-fumes-specified-substance

Last amended

Inhaling mustard gas

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/inhaling-mustard-gas

Last amended

Inhaling respirable asbestos fibres in an enclosed space

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/inhaling-respirable-asbestos-fibres-enclosed-space

Last amended

Inhaling respirable asbestos fibres in an open environment

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/inhaling-respirable-asbestos-fibres-open-environment

Last amended

Inhaling respirable crystalline silica dust

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/inhaling-respirable-crystalline-silica-dust

Last amended

No appropriate clinical management for malignant neoplasm of the lung

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/no-appropriate-clinical-management-malignant-neoplasm-lung

Last amended

Pipe smoking

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/pipe-smoking

Last amended

Silicosis

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/silicosis

Last amended

Smoking tobacco products - material contribution

Current RMA Instruments
Reasonable Hypothesis SOP
86 of 2023 as amended
Balance of Probabilities SOP
87 of 2023 as amended

Changes from previous Instruments

ICD Coding

ICD-10-AM Codes: C33, C44, D02.1, D02.2

Brief description

This is a primary malignant neoplasm of the lung. That is the neoplasm has originated in the lung or trachea (primary) and has not migrated from another primary site (secondary or metastasis). The lung tissue includes the alveoli, bronchioles, bronchi, and trachea, but not the pleura.

Confirming the diagnosis

The diagnosis requires histology.  This usually involves obtaining tissue from a biopsy of the lung.  A diagnosis based on cytology can be used if biopsy and histopathology are not readily obtainable.

The appropriate medical specialist is a respiratory physician, thoracic surgeon or oncologist.

Additional diagnoses covered by these SOPs

  • Adenocarcinoma of the lung
  • Carcinosarcoma of the lung
  • Large cell carcinoma of the lung
  • Large cell neuroendocrine carcinoma of the lung
  • Lymphoepithelial carcinoma of the lung 
  • Non-small cell carcinoma of the lung
  • Oat cell carcinoma of the lung
  • Primary melanoma of the lung
  • Small cell carcinoma of the lung
  • Small cell lung cancer
  • Squamous cell carcinoma of the lung
  • Undifferentiated carcinoma of the lung

Conditions not covered by these SOPs

  •  Carcinoid tumour of lung (typical and atypical)#
  •  Hodgkin lymphoma* of the lung
  •  Malignant melanoma
  •  Mesenchymal tumours:
    • Soft tissue sarcoma of the lung * Soft tissue sarcoma SOP
  •  Mesothelioma*
  •  Non-Hodgkin lymphoma*  Non- Hodgkin lymphoma SOP
  •  Secondary/metastatic cancer involving the lung   (code to primary cancer site)

* another SOP applies  

# non-SOP condition

Clinical onset

The condition may be dected incidentally on radiological imaging.  Typical presenting symptoms are cough, haemoptosis (coughing blood), dyspnoea (shortness of breath) or chest pain.  Patients presenting with clinical features typically have advanced disease. However, the above symptoms may all be features of other diseases.  Once the diagnosis has been confirmed it may be possible to back date onset to an earlier time based on the clinical picture.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Appropriate management of the disease varies considerably with the type and stage of the disease and other factors.  A delay in obtaining treatment could lead to a worsening of the prognosis.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/alphabetic-index-statements-principles/m/malignant-neoplasm-lung-b004/factors-ccps-18-july-2007-b004/smoking-tobacco-products-material-contribution

Last amended